Quotient Clinical Receives MHRA Supplementary Accreditation

08-Jul-2009 - United Kingdom

Quotient Clinical announces that it has been awarded Supplementary accreditation from the Medicines and Healthcare products Regulatory Agency (MHRA). This is one of the highest levels of accreditation in Europe and confirms that Quotient Clinical is qualified to perform the full range of Phase I trials, including First-in-Human (FIH) studies for low molecular weight chemical entities and biologics.

The MHRA voluntary accreditation scheme was introduced in April 2008 in line with recommendations from the MHRA clinical trial expert advisory group, to maximise subject safety, and provides formal guidance on the standards expected in a clinical unit conducting FIH studies.

Other news from the department politics & laws

Most read news

More news from our other portals

Fighting cancer: latest developments and advances